InflaRx to Showcase Vilobelimab’s Role in Immuno-Dermatology at the 2025 AAD Annual Meeting

Core Insights - InflaRx N.V. announced the acceptance of all submitted abstracts for vilobelimab at the 2025 American Academy of Dermatology Annual Meeting, highlighting its role in treating pyoderma gangrenosum (PG) and hidradenitis suppurativa (HS) [1][2] Company Overview - InflaRx is a biopharmaceutical company focused on developing anti-inflammatory therapeutics, particularly targeting the complement system with its lead product vilobelimab, a first-in-class monoclonal antibody [14] - The company has received orphan drug designation for vilobelimab from both the FDA and EMA for the treatment of PG, as well as fast track designation from the FDA [7][8] Clinical Developments - The abstracts accepted for presentation include studies on vilobelimab's safety and efficacy in PG and HS, with specific focus on the reduction of draining tunnels in HS patients [2][4] - A Phase 2a explorative dose-finding study on vilobelimab's safety in PG patients will be presented, along with pharmacokinetic and pharmacodynamic analyses [3][5] - The company is also conducting a Phase 3 trial for PG, indicating ongoing commitment to advancing vilobelimab's clinical development [7] Regulatory Status - In the U.S., vilobelimab (marketed as GOHIBIC) has received Emergency Use Authorization for treating COVID-19 in hospitalized adults, although it remains investigational and not fully approved for any indication [9][10] - In the EU, GOHIBIC has been granted marketing authorization under exceptional circumstances for treating ARDS in COVID-19 patients, supported by positive results from the Phase 3 PANAMO trial [11][12]